Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Has Average Target Price of $155.56 According to Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned an average recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $155.56.

Several research analysts recently weighed in on MIRM shares. Citigroup raised their target price on Mirum Pharmaceuticals from $184.00 to $194.00 and gave the company a “buy” rating in a research note on Wednesday. Evercore reiterated an “outperform” rating and issued a $146.00 price target on shares of Mirum Pharmaceuticals in a research report on Tuesday, October 13th. Leerink Partners dropped their price target on shares of Mirum Pharmaceuticals from $154.00 to $140.00 and set an “outperform” rating on the stock in a research report on Thursday, November 5th. Weiss Ratings downgraded shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 22nd. Finally, Morgan Stanley raised their price objective on shares of Mirum Pharmaceuticals from $137.00 to $152.00 and gave the company an “overweight” rating in a research report on Monday, October 12th.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, Director Laura Brege sold 14,167 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $94.21, for a total transaction of $1,334,673.07. Following the transaction, the director owned 15,703 shares of the company’s stock, valued at $1,479,379.63. The trade was a 47.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the transaction, the chief executive officer directly owned 194,440 shares in the company, valued at $19,187,339.20. The trade was a 13.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 104,825 shares of company stock valued at $10,160,873 over the last ninety days. Corporate insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC lifted its stake in shares of Mirum Pharmaceuticals by 87.8% in the third quarter. Steward Partners Investment Advisory LLC now owns 20,123 shares of the company’s stock valued at $1,720,000 after buying an additional 9,409 shares during the period. HighVista Strategies LLC raised its holdings in Mirum Pharmaceuticals by 79.0% in the 3rd quarter. HighVista Strategies LLC now owns 26,660 shares of the company’s stock valued at $2,279,000 after acquiring an additional 11,768 shares in the last quarter. Bleakley Financial Group LLC bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $1,128,000. Impax Asset Management Group plc bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $8,548,000. Finally, Ground Swell Capital LLC bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $564,000.

Mirum Pharmaceuticals Stock Up 0.7%

Shares of MIRM stock traded up $0.66 on Friday, hitting $93.99. The stock had a trading volume of 331,049 shares, compared to its average volume of 616,358. The firm has a market capitalization of $6.14 billion, a price-to-earnings ratio of -6.08 and a beta of 0.75. The stock’s 50 day moving average is $88.79 and its 200-day moving average is $98.41. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.98 and a current ratio of 2.07. Mirum Pharmaceuticals has a 52-week low of $63.23 and a 52-week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. The business had revenue of $185.72 million during the quarter, compared to analyst estimates of $178.07 million. During the same quarter last year, the firm posted $0.05 EPS. The company’s revenue was up 39.6% compared to the same quarter last year. As a group, research analysts expect that Mirum Pharmaceuticals will post -1.47 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.